Polyvalent Antivenom (Premium-PANAF) for Snakebite Envenoming in Ethiopia
Recruiting
Observational Study
Snake Envenomation
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
No Study Drug
Researchers observe your health over time — no experimental treatment is given.
At a Glance
- Sex
- Any
- Study type
- Observational
- Participants needed
- 600 (estimated)
- Sponsor
- Medecins Sans Frontieres, Netherlands · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
Snakebite Envenomation is recognised as a Neglected Tropical Diseases with high lethality in Sub-Saharan Africa. The current syndromic treatment approach is also fraught by supply pipeline constraints and need for cold-chain, thus negatively impacting outcomes in resource limited settings.
Despite the lack of clinical outcome data from studies in humans, after a comprehensive risk-benefit assessm…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion criteria
* Snakebite envenoming patients who receive Premium-PANAF antivenom
* Patients who have given written informed consent .
Exclusion criteria
* Snakebite envenoming patients who do not receive Premium-PANAF antivenom
* Patients referred from other centres who already received oth…
Contacts
No contact information available.